Abstract: The present disclosure provides systems and methods for receiving an input signal from a touch-sensitive interface via a first electrode associated with a tip of an active stylus. An input signal may be amplified via a control circuit that adjusts the gain of one or more amplifiers to compensate for changes in tip capacitance between the tip of the active stylus and the touch-sensitive interface. Changes in tip capacitance may be indirectly detected and compensated for by comparing the tip capacitance with that of a reference capacitor via a differential amplification circuit that includes one or more differential amplifiers.

Abstract: The present invention provides pharmacological interventions for the treatment of dyslipidemia, and to the reduction of residual risk of cardiovascular disease and adverse cardiovascular events in patients on intense statin use or with well-controlled LDL-C concentrations. In particular, the invention relates to the use of pemafibrate to prevent cardiovascular events in populations at-risk due to risk factors such as type 2 diabetes mellitus with dyslipidemia in spite of intense statin use or well-controlled LDL-C.

Abstract: The present invention relates to pharmacological interventions with pemafibrate for cardiovascular diseases and adverse cardiovascular events. In addition, the invention relates to the use of pemafibrate to treat dyslipidemia and type 2 diabetes mellitus and thereby reduce the risk of cardiovascular disease and adverse cardiovascular events.

Abstract: The present disclosure provides systems and methods for receiving an input signal from a touch-sensitive interface via a first electrode associated with a tip of an active stylus. An input signal may be amplified via a control circuit that adjusts the gain of one or more amplifiers to compensate for changes in tip capacitance between the tip of the active stylus and the touch-sensitive interface. Changes in tip capacitance may be indirectly detected and compensated for by comparing the tip capacitance with that of a reference capacitor via a differential amplification circuit that includes one or more differential amplifiers.

Abstract: Disclosed herein are nutrient delivery systems comprising a pod and a nutritional powder comprising a human milk oligosaccharide or a precursor thereof.

Abstract: This invention pertains to a method for the treatment of non-small cell lung cancer in a subject who is a smoker, comprising administering to the subject an effective amount of 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (veliparib or ABT-888), or a pharmaceutically acceptable salt thereof, in combination with carboplatin and paclitaxel.

Abstract: This invention pertains to a method for the treatment of non-small cell lung cancer in a subject who is a smoker, comprising administering to the subject an effective amount of 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (veliparib or ABT-888), or a pharmaceutically acceptable salt thereof, in combination with carboplatin and paclitaxel.

Abstract: A robotic building system includes a first through third sets of extruded elements integrally joined at lengthwise edges and corners to rails. The second set of extruded elements has at least three adjoining sides surrounding a hollow opening, where each side is integrally joined to a rail. A third set of extruded elements has an asymmetrical inside angle shaped element formed by a first web and a second web oriented generally perpendicular to the first web, where each web is integrally affixed between a pair of opposing rails and each web shares a common rail. The rails may be tapped or drilled to accept a fastener, and each extruded element of the first set, second set and third set of extruded elements are adapted to be flush mounted to any of the other extruded elements or to the same shape extruded elements.

Abstract: The invention relates to a method for the treatment of triple negative breast cancer in a subject, comprising administering to the subject an effective amount of 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide, or a pharmaceutically acceptable salt thereof, and an effective amount of carboplatin, in combination with standard of care.

Abstract: The invention relates to a method for the treatment of triple negative breast cancer in a subject, comprising administering to the subject an effective amount of 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide, or a pharmaceutically acceptable salt thereof, and an effective amount of carboplatin, in combination with standard of care.

Abstract: A robotic building system includes a first through third sets of extruded elements integrally joined at lengthwise edges and corners to rails. The second set of extruded elements has at least three adjoining sides surrounding a hollow opening, where each side is integrally joined to a rail. A third set of extruded elements has an asymmetrical inside angle shaped element formed by a first web and a second web oriented generally perpendicular to the first web, where each web is integrally affixed between a pair of opposing rails and each web shares a common rail. The rails may be tapped or drilled to accept a fastener, and each extruded element of the first set, second set and third set of extruded elements are adapted to be flush mounted to any of the other extruded elements or to the same shape extruded elements.

Abstract: This invention pertains to a method for the treatment of non-small cell lung cancer in a subject who is a smoker, comprising administering to the subject an effective amount of 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (veliparib or ABT-888), or a pharmaceutically acceptable salt thereof, in combination with carboplatin and paclitaxel.

Abstract: The invention relates to a method for the treatment of triple negative breast cancer in a subject, comprising administering to the subject an effective amount of 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide, or a pharmaceutically acceptable salt thereof, and an effective amount of carboplatin, in combination with standard of care.

Abstract: Methods of wireless communication between a gaming console and a wireless accessory using a protocol. The protocol is used in a TDMA frequency hopping spread spectrum system to enable simultaneous communication of voice and data between a plurality of wireless accessories and the gaming console. The protocol provides specific time slots for upstream and downstream transmissions, as well as a retransmission time slots to enable a robust environment with minimal latency.

Abstract: Methods of reducing the number of platelets in mammals and preventing or treating pro-thrombotic conditions and diseases that are characterized by an excess of, or undesired activation of, platelets using inhibitors of anti-apoptotic Bcl-2 family protein members is disclosed.

Abstract: Methods of wireless communication between a gaming console and a wireless accessory using a protocol. The protocol is used in a TDMA frequency hopping spread spectrum system to enable simultaneous communication of voice and data between a plurality of wireless accessories and the gaming console. The protocol provides specific time slots for upstream and downstream transmissions, as well as a retransmission time slots to enable a robust environment with minimal latency.

Abstract: Methods of wireless communication between a gaming console and a wireless accessory using a protocol. The protocol is used in a TDMA frequency hopping spread spectrum system to enable simultaneous communication of voice and data between a plurality of wireless accessories and the gaming console. The protocol provides specific time slots for upstream and downstream transmissions, as well as a retransmission time slots to enable a robust environment with minimal latency.

Abstract: Methods of reducing the number of platelets in mammals and preventing or treating pro-thrombotic conditions and diseases that are characterized by an excess of, or undesired activation of, platelets using inhibitors of anti-apoptotic Bcl-2 family protein members is disclosed.